| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/09/2006 | US20060051357 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and or a mtor inhibitor |
| 03/09/2006 | US20060051350 Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GITR or TNFRSF18) |
| 03/09/2006 | US20060051349 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/09/2006 | US20060051343 Preventives remedies for bone and joint diseases |
| 03/09/2006 | US20060051339 Composition for treatment of oily skin and acne prevention and methods of making and using same |
| 03/09/2006 | US20060051335 fusing cells: nucleic acid vector comprises a nucleotide sequence encoding a syncytium-inducing polypeptide that is expressible on a eukaryotic cell surface and comprises a sequence of a gibbon ape leukemia virus |
| 03/09/2006 | US20060051323 Formulations comprising vitamin b12, method of production and use thereof |
| 03/09/2006 | US20060051320 Lyophilized formulations of pegylated interferon which are prepared using trehalose as a cryoprotectant; formulations have a low moisture content, which helps stabilize the pegylated interferon during storage at room temperature |
| 03/09/2006 | US20060051319 Neuroprotective effect of solubilized UDCA in focal ischemic model |
| 03/09/2006 | US20060051317 Amphiphilic polymer-protein conjugates and methods of use thereof |
| 03/09/2006 | US20060051316 Remedy |
| 03/09/2006 | US20060051315 Polymers for delivering peptides and small molecules in vivo |
| 03/09/2006 | US20060051314 Drug for prevention and/or treatment of constipation and sympton caused by constipation |
| 03/09/2006 | US20060051313 Star polymer of calixarenes branching with copolymer of tert-butyl acrylate-butyl acrylate; use for hair styling, retaining hair shape; hair sprays, lacquers, foams, creams, gels, emulsions, lotions, and waxes |
| 03/09/2006 | US20060051300 Formulations and methods for treating rhinosinusitis |
| 03/09/2006 | US20060051299 Fluticasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; rhinitis treatment |
| 03/09/2006 | US20060051296 Thickened beverages for dysphagia |
| 03/09/2006 | US20060051295 Estrogen receptor interaction with a transcription factor |
| 03/09/2006 | US20060051293 noninvasive technique for imaging and quantitating amyloid deposits; 2-phenyl- imidazo [1,2,a] pyridine derivatives; radiolabelling; drug delivery; 2-(4'-dimethylaminophenyl)-6-iodobenzothiazole |
| 03/09/2006 | US20060048780 Dry powder dispersing apparatus and methods for their use |
| 03/09/2006 | DE4116123B4 Mittel zur Behandlung von Hauterkrankungen Agents for the treatment of skin diseases |
| 03/09/2006 | DE19681616B4 Prozeß zur Gewinnung von Oestrogenen aus Stutenharn Process for the production of estrogens from Stutenharn |
| 03/09/2006 | DE10231627B4 Heterozyklisch substituierte Benzoylharnstoffe und ihre Verwendung als Arzneimittel Heterocyclic unsubstituted benzoyl ureas and their use as a medicament |
| 03/09/2006 | DE102004042607A1 Substituierte Phenylaminothiazole und ihre Verwendung Substituted Phenylaminothiazole and their use |
| 03/09/2006 | DE102004040630A1 Kombinationstherapie mit Procain Combination therapy with procaine |
| 03/09/2006 | DE102004040006A1 Pharmazeutische Zusammensetzung, umfassend Galaktose, Selen, Vitamin E und/oder Phosphatidylcholin und pharmazeutische Verwendung von Galaktose A pharmaceutical composition comprising galactose, selenium, vitamin E and / or phosphatidylcholine and pharmaceutical use of galactose |
| 03/09/2006 | CA2752569A1 .delta.-amino acid as an exercise function-improving agent |
| 03/09/2006 | CA2617601A1 Methods and materials relating to enhanced production of dopamine neurons |
| 03/09/2006 | CA2579776A1 Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp) |
| 03/09/2006 | CA2579089A1 Inhibition of viruses using rnase h inhibitors |
| 03/09/2006 | CA2579078A1 Cyclopamine analogues and methods of use thereof |
| 03/09/2006 | CA2578995A1 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use |
| 03/09/2006 | CA2578993A1 Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides |
| 03/09/2006 | CA2578955A1 Isoindolin-1-one derivatives |
| 03/09/2006 | CA2578852A1 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
| 03/09/2006 | CA2578784A1 Compositions containing alpha-2-adrenergic agonist components |
| 03/09/2006 | CA2578781A1 Fused tricyclic derivatives for the treatment of psychotic disorders |
| 03/09/2006 | CA2578780A1 Hexahydro-pyrazino[1,2-a]pyrimidine-4, 7-dione derivatives substituted with amino acids |
| 03/09/2006 | CA2578772A1 Diphenylethylene compounds and uses thereof |
| 03/09/2006 | CA2578746A1 Chemical compounds |
| 03/09/2006 | CA2578743A1 Partial and full agonists of a1 adenosine receptors |
| 03/09/2006 | CA2578683A1 Transgenic mammals and cell lines for the identification of glutamate transporter modulators |
| 03/09/2006 | CA2578630A1 Pyrimidinylimidazoles as tgf-beta inhibitors |
| 03/09/2006 | CA2578628A1 Pyrimidinylpyrazoles as tgf-beta inhibitors |
| 03/09/2006 | CA2578604A1 Piperidine derivative or pharmaceutically acceptable salt thereof |
| 03/09/2006 | CA2578552A1 Medicinal composition for percutaneous perospirone administration |
| 03/09/2006 | CA2578474A1 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
| 03/09/2006 | CA2578441A1 Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| 03/09/2006 | CA2578438A1 Pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoro methyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid |
| 03/09/2006 | CA2578368A1 Triazolophthalazines |
| 03/09/2006 | CA2578347A1 Mitochondria activators |
| 03/09/2006 | CA2578194A1 Androgen modulators |
| 03/09/2006 | CA2578184A1 Combination of substituted benzimidazoles and triazine derivatives with antiparasitic action |
| 03/09/2006 | CA2578044A1 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
| 03/09/2006 | CA2578016A1 Azabicyclic histamine-3 receptor antagonists |
| 03/09/2006 | CA2577964A1 Ligands for g-protein coupled receptors |
| 03/09/2006 | CA2577947A1 Novel substituted imidazole derivative |
| 03/09/2006 | CA2577928A1 Molecular chaperone function regulator |
| 03/09/2006 | CA2577925A1 Substituted indole compounds and their use as 5-ht6 receptor modulators |
| 03/09/2006 | CA2577924A1 Novel carbapenem compound |
| 03/09/2006 | CA2577852A1 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
| 03/09/2006 | CA2577702A1 New polymorphic form of inulin and uses thereof |
| 03/09/2006 | CA2577398A1 Urea derivatives as calcium channel blockers |
| 03/09/2006 | CA2577392A1 Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors |
| 03/09/2006 | CA2577311A1 Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin |
| 03/09/2006 | CA2577301A1 Substituted biaryl piperazinyl-pyridine analogues |
| 03/09/2006 | CA2577284A1 Prostaglandin derivatives for treating gastrointestinal disorder |
| 03/09/2006 | CA2577278A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 03/09/2006 | CA2577275A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 03/09/2006 | CA2577273A1 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
| 03/09/2006 | CA2577268A1 Neuroprotective effect of solubilized udca in focal ischemic model |
| 03/09/2006 | CA2577222A1 Isoindoline compounds and methods of making and using the same |
| 03/09/2006 | CA2576988A1 Androgen receptor modulators |
| 03/09/2006 | CA2576959A1 Histone deacetylase inhibitors |
| 03/09/2006 | CA2576924A1 Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 03/09/2006 | CA2576850A1 Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 03/09/2006 | CA2576839A1 N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 03/09/2006 | CA2576832A1 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 03/09/2006 | CA2576830A1 Arylamine ketones, their preparation methods, the pharmaceutical compositions containing them and their use |
| 03/09/2006 | CA2576827A1 Vegf inhibition |
| 03/09/2006 | CA2576818A1 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 03/09/2006 | CA2576812A1 Method for the treatment of attention deficit hyperactivity disorder |
| 03/09/2006 | CA2576782A1 Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors |
| 03/09/2006 | CA2576781A1 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof |
| 03/09/2006 | CA2576765A1 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 03/09/2006 | CA2576727A1 N(1 h-indolyl)-1 h-indole-2-carb0xamide derivatives, their preparation and their therapeutic use |
| 03/09/2006 | CA2576721A1 Use of dendrimers to stimulate cell growth |
| 03/09/2006 | CA2576717A1 Pyrrole derivatives, their preparation and their therapeutic use |
| 03/09/2006 | CA2576353A1 Prodrug substituted benzoxazoles as estrogenic agents |
| 03/09/2006 | CA2576307A1 Crystalline forms of 1,24(s)-dihydroxy vitamin d2 |
| 03/09/2006 | CA2576275A1 Multiparticulates with controlled release properties and free of lubricant |
| 03/09/2006 | CA2572442A1 Hybrid qa molecules wherein q is an aminoquinoline and a is an antibiotic residue, their synthesis and their uses as antibacterial agent |
| 03/09/2006 | CA2571989A1 Modulators of nuclear receptors |
| 03/09/2006 | CA2567377A1 Inhibition of atherosclerosis by diindolylmethane analogs |
| 03/09/2006 | CA2554420A1 Topical otic compositions and methods of topical treatment or prevention of otic infections |
| 03/08/2006 | EP1632499A2 Gene sequences amplified in tumours and their diagnostic uses |
| 03/08/2006 | EP1632494A1 Vasopressin v1a antagonists |
| 03/08/2006 | EP1632493A1 Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| 03/08/2006 | EP1632492A1 Tricyclic compound |
| 03/08/2006 | EP1632491A1 Substituted indole compounds and their use as 5-HT6 receptor modulators |